| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fa9993bc2e6a032b3d8731b4c4e12a6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-292
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 |
| filingDate |
2015-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33128a1782fb00153a02ac7d41f899dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c98b2855cc4d7f12c4b93b778ee1fee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e73e8a5f27597e45f86d988700a0796 |
| publicationDate |
2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10183962-B2 |
| titleOfInvention |
Synthetic oligomers of Neisseria meningitis serogroup X and process of preparing them |
| abstract |
The present invention relates to synthesis of novel higher oligomers and process of preparing the same. In particular the present invention relates to the chemical synthesis of oligomers of Neisseria meningitidis serogroup X (‘hereinafter Men-X), more particularly tetramer. The present invention provides Men-X capsular oligomers obtained from synthetic pathway using purified saccharides of specific chain length and provides said novel oligomers as candidates for the development of conjugate vaccine against bacterial meningitis caused due to Men-X infections. |
| priorityDate |
2014-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |